Status:
COMPLETED
Treatment of Suicidal Ideation With Intravenous Ketamine Infusion
Lead Sponsor:
University of Alabama at Birmingham
Conditions:
Depression
Suicidal Ideation
Eligibility:
All Genders
19+ years
Phase:
NA
Brief Summary
This study is dedicated to achieving better treatments for suicidal thoughts. Specifically, the investigators are studying the effect of a medication called ketamine to quickly treat suicidal thoughts...
Detailed Description
This study is dedicated to achieving better treatments for suicidal thoughts. Specifically, we are studying the effect of a medication called ketamine to quickly treat suicidal thoughts and depression...
Eligibility Criteria
Inclusion
- Age : 19-64
- Significant suicidality score on the Columbia Suicide Severity Rating Scale (C-SSRS)
- Willing and able to provide informed consent.
- Individuals with current substance abuse are allowed
Exclusion
- Pregnant or lactating; women of reproductive potential must have a negative urine pregnancy test (urine dipstick method)
- Post-Partum state : defined as being within 2 months of delivery or miscarriage
- Homicide risk as determined by clinical interview
- Treatment with any medication known to specifically target the glutamate-NMDA receptor system (ie lamotrigine, acamprosate, memantine, riluzole or lithium)
- Any known hypersensitivity or serious adverse effect associated with ketamine treatment.
- Any clinically significant medical condition or therapy that would preclude treatment with ketamine, to include recent myocardial infarction or unstable angina
- Medically unstable, including acute withdrawal from alcohol or benzodiazepines requiring the use of benzodiazepine treatment.
- Any of the following DSM-IV diagnoses or categories:
- Any current psychosis or history of a non-mood psychotic disorder (e.g., schizophrenia)
- Currently in a manic or mixed episode
- Current use (defined by urine dipstick test) or abuse of hallucinogenic drugs (except marijuana) such as phencyclidine
- Any dissociative disorder
- Any pervasive developmental disorder (e.g., autism)
- A cognitive disorder (e.g., Alzheimer's Disease)
- Cluster A personality disorder (e.g., schizoid or schizotypal); note that cluster B and C personality disorders may be included
- Any eating disorder
Key Trial Info
Start Date :
May 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2014
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT01887990
Start Date
May 1 2012
End Date
January 1 2014
Last Update
May 15 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama Birmingham
Birmingham, Alabama, United States, 35205